Hit by 2 more flops, Bristol Myers and Nektar wind down IL-2/PD-1 program at the center of $3.6B deal
Four years after Bristol Myers Squibb paid a record-breaking $1.85 billion in cash to partner with Nektar Therapeutics and launch a sprawling clinical program to test its IL-2 drug in combination with the pharma giant’s anchoring PD-1 inhibitor, the companies are calling it quits.
The global development program for bempegaldesleukin plus Opdivo will come to an end in what BMS and Nektar described as a joint decision, they announced on Thursday in the wake of two more negative late-stage readouts.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.